Dyadic International (NASDAQ:DYAI) Major Shareholder Francisco Trust Under Agreemen Sells 20,000 Shares

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 20,000 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $1.92, for a total value of $38,400.00. Following the transaction, the insider directly owned 3,390,664 shares of the company’s stock, valued at approximately $6,510,074.88. This represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Dyadic International Trading Up 10.1%

Shares of NASDAQ:DYAI opened at $1.06 on Tuesday. Dyadic International Inc. has a 52 week low of $0.65 and a 52 week high of $1.35. The company’s 50 day moving average is $0.77 and its two-hundred day moving average is $0.83. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. The company has a market cap of $38.81 million, a PE ratio of -4.70 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. Equities analysts predict that Dyadic International Inc. will post 0.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Dyadic International currently has an average rating of “Hold” and a consensus target price of $3.00.

Dyadic International News Roundup

Here are the key news stories impacting Dyadic International this week:

• Positive Sentiment: Dyadic said global collaborations continue to validate its C1 protein-expression platform and expand its commercial opportunity, reinforcing the investment case around its core biotechnology technology. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
• Neutral Sentiment: The company’s latest reported quarterly results were mixed, with revenue beating expectations but earnings per share missing estimates, leaving investors focused on future commercialization progress rather than near-term profitability.
• Negative Sentiment: Major shareholder Francisco Trust Under Agreemen disclosed additional stock sales, adding to recent insider selling that may create some caution around the stock’s near-term momentum.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 36,266 shares during the last quarter. Marathon Capital Management grew its holdings in shares of Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 50,000 shares during the last quarter. Apis Capital Advisors LLC acquired a new stake in shares of Dyadic International during the third quarter worth about $1,817,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International during the third quarter worth about $190,000. Finally, Bank of America Corp DE lifted its holdings in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.